CICM examiner reports · fix it Missing the detail in the stem Skipping the age, medicine, allergy or setting that changes the answer.
What it looks like: One line in the stem (a current medicine, pregnancy, kidney function, an allergy, a rural setting) makes the usual answer wrong. Reading for the diagnosis and skimming the rest misses it.
How to fix it: Before answering, list the patient's medicines, conditions and setting from the stem. For each option you like, check it against that list for interactions and contraindications.
The drill: 15 questions Questions from the Intensive care bank picked because they test this habit. You answer one at a time and see the explanation straight away.
The first 3 are free, below and in the drill with a free account. Any Intensive care plan opens all 15.
Try 3 now. No account needed. Question 1 of 3 Sepsis, microbiology and antimicrobials
A 62-year-old woman is admitted with severe community-acquired pneumonia needing high-flow nasal oxygen at FiO2 0.6. Her blood pressure is 112/64 mmHg without vasopressors. Influenza and SARS-CoV-2 PCR are negative and she has no contraindication to corticosteroid. A trainee asks about adjunctive hydrocortisone. Which statement best reflects the current evidence? A Benefit has been shown only in septic shock, so it should be withheld B Benefit has been shown only in Legionella infection, so it should await testing C A trial in severe pneumonia without shock showed reduced 28-day mortality D A trial in severe pneumonia without shock showed increased 28-day mortality
Pick an answer to see the explanation. Next question →
Question 1 of 3 · Sepsis, microbiology and antimicrobials
A 62-year-old woman is admitted with severe community-acquired pneumonia needing high-flow nasal oxygen at FiO2 0.6. Her blood pressure is 112/64 mmHg without vasopressors. Influenza and SARS-CoV-2 PCR are negative and she has no contraindication to corticosteroid. A trainee asks about adjunctive hydrocortisone. Which statement best reflects the current evidence?
Benefit has been shown only in septic shock, so it should be withheld Benefit has been shown only in Legionella infection, so it should await testing A trial in severe pneumonia without shock showed reduced 28-day mortality A trial in severe pneumonia without shock showed increased 28-day mortality Show the answer C. A trial in severe pneumonia without shock showed reduced 28-day mortality
CAPE COD randomised adults with severe community-acquired pneumonia requiring intensive care, excluding septic shock and influenza, to early intravenous hydrocortisone 200 mg daily with a taper, or placebo, and found 28-day mortality fell from about 12 to 6 per cent, with fewer intubations. This patient fits those criteria: severe hypoxaemia, no vasopressors and influenza excluded. Benefit is not restricted to Legionella or to shock, and harm has been shown in influenza pneumonia. Results of other trials, including a trial of methylprednisolone in veterans, have been less consistent, so local guidance should be followed. Hyperglycaemia is the main adverse effect.
Why not A: CAPE COD specifically excluded septic shock and still found a mortality benefit Why not B: The randomised evidence is not restricted to Legionella and does not depend on the organism Why not D: Mortality fell rather than rose; harm has been shown in influenza pneumonia rather than in this group Question 2 of 3 · Respiratory physiology and ventilation
A 72-year-old man who has never smoked takes slow-release oral theophylline for chronic obstructive pulmonary disease, with a stable level of 10 mg/L. Four days after starting oral ciprofloxacin for a urinary infection he presents with vomiting, a sinus tachycardia of 140/min and a generalised seizure. His theophylline level is 34 mg/L. Which mechanism explains the interaction?
Ciprofloxacin inhibits CYP1A2, the main enzyme metabolising theophylline Ciprofloxacin displaces theophylline from plasma albumin binding sites Ciprofloxacin reduces the renal tubular secretion of unchanged theophylline Ciprofloxacin induces CYP3A4, forming a toxic theophylline metabolite Show the answer A. Ciprofloxacin inhibits CYP1A2, the main enzyme metabolising theophylline
Theophylline is cleared mainly by hepatic metabolism through CYP1A2, with a minor CYP2E1 and CYP3A4 contribution. Ciprofloxacin is a potent CYP1A2 inhibitor and can roughly double theophylline levels within days; erythromycin, clarithromycin, fluvoxamine and cimetidine also raise levels. Because theophylline has a narrow therapeutic range (about 10 to 20 mg/L, or 55 to 110 micromol/L), toxicity appears as vomiting, tachyarrhythmias, hypokalaemia and seizures, which may be refractory. Smoking induces CYP1A2, so stopping smoking also raises levels, but he has never smoked. Protein binding displacement and renal effects are minor, and ciprofloxacin is not an inducer. References: Goodman and Gilman's The Pharmacological Basis of Therapeutics; Australian Medicines Handbook.
Why not B: Theophylline is only about 40% protein bound, and displacement would not cause a sustained threefold rise. Why not C: Only about 10% of theophylline is excreted unchanged in urine in adults, so renal effects are minor. Why not D: Ciprofloxacin is an enzyme inhibitor rather than an inducer, and the toxicity is from theophylline itself. Question 3 of 3 · Haematology and transfusion
A 52-year-old man on venoarterial ECMO for cardiogenic shock has a fall in platelets from 210 to 70 x 10^9/L on day 7, with a positive anti-PF4 immunoassay and a strongly positive functional assay. He has ischaemic hepatitis with a bilirubin of 95 micromol/L and an INR of 2.4, and is on CRRT. Which anticoagulant strategy is most appropriate?
Argatroban at the standard dose, as its clearance is unaffected by renal failure Fondaparinux once daily, as ECMO circuits tolerate factor Xa inhibition well Bivalirudin titrated to aPTT, as it is cleared mainly by enzymatic proteolysis A switch to low molecular weight heparin, which rarely cross-reacts in HIT Show the answer C. Bivalirudin titrated to aPTT, as it is cleared mainly by enzymatic proteolysis
Confirmed heparin-induced thrombocytopenia requires immediate cessation of all heparin, including circuit flushes and heparin-coated lines where feasible, and a non-heparin anticoagulant at therapeutic intensity. Bivalirudin is a short-acting direct thrombin inhibitor (half-life about 25 minutes) cleared mainly by proteolytic cleavage, with a smaller renal component, so it is well suited to a patient with hepatic dysfunction on ECMO and CRRT, with dose titrated to aPTT or anti-IIa assays. Argatroban is hepatically cleared, and in hepatic impairment and critical illness its clearance falls markedly, so a standard dose risks accumulation and bleeding; it also raises the INR. Fondaparinux is renally eliminated with a long half-life, which is unsuitable in renal failure and difficult to titrate on ECMO. Low molecular weight heparin cross-reacts with HIT antibodies and is contraindicated. References: Cuker A, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018;2:3360-92; McMichael ABV, et al. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J 2022;68:303-10.
Why not A: Argatroban is hepatically cleared and accumulates in liver dysfunction, so a standard dose is unsafe. Why not B: Fondaparinux is renally cleared with a long half-life, unsuitable in renal failure on ECMO. Why not D: Low molecular weight heparin cross-reacts with HIT antibodies and is contraindicated. Create a free account to save your results and keep going →
Where the CICM examiners flagged it All CICM examiner reports →
Fellowship Ready is not affiliated with or endorsed by the CICM. Not affiliated with the CICM.